Fra studiets måned 14, fik de simuleret injektionsbehandlende patienter tilladelse til at få ranibizumab- behandling, og fra måned 19, var hyppigere behandlinger muligt.
From month 14 of the study, sham- treated patients were allowed to cross over to receive ranibizumab and from month 19, more frequent treatments were possible.